Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
This article was originally published in The Pink Sheet Daily
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.
You may also be interested in...
FDA isn't alone monitoring drug, medical device and food companies making false Covid-19 treatment claims. New York AG warns Jim Bakker, UK agency cuts off face mask ads, Amazon removes thousands of products priced to cheat fearful consumers and Facebook cuts false ads.
Mary Engle led FTC enforcement actions including against POM Wonderful’s claims for its pomegranate supplements; Huber is CRN’s scientific and regulatory affairs VP and Amanda Darlington is government relations director; Jones takes charge of Nature’s Bounty supply chain; and Benev Co. names five aesthetic experts to Medical Advisory Board to advance its “medically developed cosmeceutical line.”
Therapeutic Solutions says animal study data show synergy in use of NanoStilbene, its proprietary formulation of pterostilbene, together with anti-CTLA4 antibody, "the mouse equivalent" of ipilimumab, an immunotherapeutic in the "checkpoint inhibitors" family of drugs. It also notes early results of clinical trial with cancer patients suggesting NanoStilbene efficacy in increased activity of immune system "natural killer" cells and enhanced production of interferon gamma, a protein associated with cancer growth suppression.